Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw

Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma... Bisphosphonates are formidable inhibitors of osteoclast-mediated bone resorption employed for therapy of multiple myeloma (MM) subjects with osteolytic lesions. Osteonecrosis of the jaw (ONJ) is an uncommon drug-induced adverse event of these agents. MicroRNAs (miRNAs) are a group of small, noncoding RNAs nucleotides, which are essential post-transcriptional controllers of gene expression. They have a central role in the normal bone development. The goal of our study was to investigate 18 miRNAs, whose targets were previously validated and described in MM subjects without ONJ, in peripheral lymphocytes of MM subjects with bisphosphonate-induced ONJ. Utilizing reverse transcription quantitative polymerase chain reaction, we evaluated miRNAs in five healthy subjects and in five MM patients with ONJ. Our experimental data revealed that a diverse miRNA signature for ONJ subjects emerged with respect to control subjects. Using the filter for in silico analysis, among the 18 miRNAs, we recognized 14 dysregulated miRNAs. All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520). Among them, six were strongly upregulated (fourfold upregulated and more). These miRNAs target numerous pathways and genes implicated in calcium ion binding, bone resorption, mineralization of bone matrix, and differentiation and maintenance of bone tissue. A modified microRNA expression profile after zoledronate therapy could participate to the onset of ONJ. Targeting these miRNAs could provide a new opportunity for the prevention or treatment of ONJ. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw

Download PDF
11 pages

Loading next page...
 
/lp/springer_journal/altered-microrna-expression-profile-in-the-peripheral-lymphoid-pAYkw5p7rm
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
DOI
10.1007/s00277-018-3296-7
pmid
29546453
Publisher site
See Article on Publisher Site

Abstract

Bisphosphonates are formidable inhibitors of osteoclast-mediated bone resorption employed for therapy of multiple myeloma (MM) subjects with osteolytic lesions. Osteonecrosis of the jaw (ONJ) is an uncommon drug-induced adverse event of these agents. MicroRNAs (miRNAs) are a group of small, noncoding RNAs nucleotides, which are essential post-transcriptional controllers of gene expression. They have a central role in the normal bone development. The goal of our study was to investigate 18 miRNAs, whose targets were previously validated and described in MM subjects without ONJ, in peripheral lymphocytes of MM subjects with bisphosphonate-induced ONJ. Utilizing reverse transcription quantitative polymerase chain reaction, we evaluated miRNAs in five healthy subjects and in five MM patients with ONJ. Our experimental data revealed that a diverse miRNA signature for ONJ subjects emerged with respect to control subjects. Using the filter for in silico analysis, among the 18 miRNAs, we recognized 14 dysregulated miRNAs. All these miRNAs were significantly over-expressed in patients vs controls (MIR-16-1, MIR-21, MIR-23A, MIR-28, MIR-101-1, MIR-124-1, MIR-129, MIR-139, MIR-145, MIR-149, MIR-202, MIR-221, MIR-424, MIR-520). Among them, six were strongly upregulated (fourfold upregulated and more). These miRNAs target numerous pathways and genes implicated in calcium ion binding, bone resorption, mineralization of bone matrix, and differentiation and maintenance of bone tissue. A modified microRNA expression profile after zoledronate therapy could participate to the onset of ONJ. Targeting these miRNAs could provide a new opportunity for the prevention or treatment of ONJ.

Journal

Annals of Hematology – Springer Journals

Published: Mar 15, 2018

References

  • Zoledronic acid (Reclast®, Aclasta®): a review in osteoporosis
    Dhillon, S
  • The role of prenylated small GTP-binding proteins in the regulation of osteoclast function
    Coxon, FP; Rogers, MJ
  • Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
    Kopecka, J; Porto, S; Lusa, S; Gazzano, E; Salzano, G; Giordano, A; Desiderio, V; Ghigo, D; Caraglia, M; Rosa, G; Riganti, C
  • Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid
    Misso, G; Porru, M; Stoppacciaro, A; Castellano, M; Cicco, F; Leonetti, C; Santini, D; Caraglia, M
  • DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by gammadelta T lymphocytes
    Nussbaumer, O; Gruenbacher, G; Gander, H; Thurnher, M
  • Zoledronic acid inhibits macrophage/microglia-assisted breast cancer cell invasion
    Rietkotter, E; Menck, K; Bleckmann, A; Farhat, K; Schaffrinski, M; Schulz, M; Hanisch, UK; Binder, C; Pukrop, T
  • Drug induced osteonecrosis of the jaw
    Hamadeh, IS; Ngwa, BA; Gong, Y
  • Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab
    Allegra, A; Oteri, G; Alonci, A; Bacci, F; Penna, G; Minardi, V; Maisano, V; Musolino, C
  • Adalimumab: another medication related to osteonecrosis of the jaws?
    Cassoni, A; Romeo, U; Terenzi, V; Della Monaca, M; Rajabtork Zadeh, O; Raponi, I; Fadda, MT; Polimeni, A; Valentini, V
  • Task force on bisphosphonate-related osteonecrosis of the jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update
    Ruggiero, SL; Dodson, TB; Assael, LA; Landesberg, R; Marx, RE; Mehrotra, B
  • Avascular necrosis of bone in leukemia and osteonecrosis of jaw by bisphosphonates
    Nastro, E; Allegra, A; Oteri, G; Ferlito, S; Alonci, A; Bellomo, G; D'Angelo, A; Tolomeo, A; Cicciù, D; Ponte, FS; Musolino, C
  • Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer
    Nastro, E; Musolino, C; Allegra, A; Oteri, G; Cicciù, M; Alonci, A; Quartarone, E; Alati, C; Ponte, FS
  • Fatigue in bone: a novel phenomenon attributable to bisphosphonate use
    Kyrgidis, A; Verrou, E
  • Teriparatide therapy for alendronate-associated osteonecrosis of the jaw
    Cheung, A; Seeman, E
  • Jaw osteonecrosis in patients treated with bisphosphonates: an ultrastructural study
    Perrotta, I; Cristofaro, MG; Amantea, M; Russo, E; Fazio, S; Zuccalà, V; Conforti, F; Amorosi, A; Donato, G; Tripepi, S; Giudice, M
  • Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases
    Filleul, O; Crompot, E; Saussez, S
  • Bone-bound bisphosphonate inhibits growth of adjacent non-bone cells
    Cornish, J; Bava, U; Callon, KE; Bai, J; Naot, D; Reid, IR
  • Immunohistochemial evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw
    Nastro Siniscalchi, E; Cutroneo, G; Catalfamo, L; Santoro, G; Allegra, A; Oteri, G; Cicciù, D; Alonci, A; Penna, G; Musolino, C; Saverio De Ponte, F; Anastasi, G; Favaloro, A
  • Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats
    Fournier, P; Boissier, S; Filleur, S; Guglielmi, J; Cabon, F; Colombel, M; Clézardin, P
  • Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients
    Santini, D; Vincenzi, B; Dicuonzo, G; Avvisati, G; Massacesi, C; Battistoni, F; Gavasci, M; Rocci, L; Tirindelli, MC; Altomare, V; Tocchini, M; Bonsignori, M; Tonini, G
  • Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws
    Allegra, A; Alonci, A; Penna, G; Granata, A; Nastro Siniscalchi, E; Oteri, G; Loddo, S; Teti, D; Cicciù, D; Ponte, FS; Musolino, C
  • Reduced serum levels of interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration
    Oteri, G; Allegra, A; Bellomo, G; Alonci, A; Nastro, E; Penna, G; Catalfamo, L; Cicciù, D; Ponte, FS; Musolino, C
  • Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1
    Alonci, A; Allegra, A; Bellomo, G; Quartarone, E; Oteri, G; Nastro, E; Cicciù, D; Ponte, FS; Musolino, C
  • Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells
    Allegra, A; Oteri, G; Nastro, E; Alonci, A; Bellomo, G; Fabro, V; Quartarone, E; Alati, C; Ponte, FS; Cicciù, D; Musolino, C
  • Genetic polymorphisms and other risk factors associated with bisphosphonate induced osteonecrosis of the jaw
    Katz, J; Gong, Y; Salmasinia, D; Hou, W; Burkley, B; Ferreira, P; Casanova, O; Langaee, TY; Moreb, JS
  • Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws
    Arduino, PG; Menegatti, E; Scoletta, M; Battaglio, C; Mozzati, M; Chiecchio, A; Berardi, D; Vandone, AM; Donadio, M; Gandolfo, S; Scully, C; Broccoletti, R
  • A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling
    Martino, MT; Arbitrio, M; Guzzi, PH; Leone, E; Baudi, F; Piro, E; Prantera, T; Cucinotto, I; Calimeri, T; Rossi, M; Veltri, P; Cannataro, M; Tagliaferri, P; Tassone, P
  • An aromatase polymorphism (g.132810C>T) predicts risk of bisphosphonate-related osteonecrosis of the jaw
    Ferla, F; Paolicchi, E; Crea, F; Cei, S; Graziani, F; Gabriele, M; Danesi, R
  • Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw
    Stockmann, P; Nkenke, E; Englbrecht, M; Schlittenbauer, T; Wehrhan, F; Rauh, C; Beckmann, MW; Fasching, PA; Kreusch, T; Mackensen, A; Wullich, B; Schett, G; Spriewald, BM
  • Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3
    Nicoletti, P; Cartsos, VM; Palaska, PK; Shen, Y; Floratos, A; Zavras, AI
  • Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis
    Sarasquete, ME; García-Sanz, R; Marín, L; Alcoceba, M; Chillón, MC; Balanzategui, A; Santamaria, C; Rosiñol, L; Rubia, J; Hernandez, MT; Garcia-Navarro, I; Lahuerta, JJ; González, M; San Miguel, JF
  • Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review)
    Allegra, A; Alonci, A; Campo, S; Penna, G; Petrungaro, A; Gerace, D; Musolino, C
  • miR-29 promotes murine osteoclastogenesis by regulating osteoclast commitment and migration
    Franceschetti, T; Kessler, CB; Lee, SK; Delany, AM
  • miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease
    Rossi, M; Pitari, MR; Amodio, N; Martino, MT; Conforti, F; Leone, E; Botta, C; Paolino, FM; Giudice, T; Iuliano, E; Caraglia, M; Ferrarini, M; Giordano, A; Tagliaferri, P; Tassone, P
  • miR-31 controls osteoclast formation and bone resorption by targeting RHOA
    Mizoguchi, F; Murakami, Y; Saito, T; Miyasaka, N; Kohsaka, H
  • miR-214 promotes osteoclastogenesis by targeting pten/pi3k/akt pathway
    Zhao, C; Sun, W; Zhang, P; Ling, S; Li, Y; Zhao, D; Peng, J; Wang, A; Li, Q; Song, J; Wang, C; Xu, X; Xu, Z; Zhong, G; Han, B; Chang, YZ; Li, Y
  • miR-148a regulates osteoclastogenesis by targeting v-maf musculo aponeurotic fibrosarcoma oncogene homolog b
    Cheng, P; Chen, C; He, HB; Hu, R; Zhou, HD; Xie, H; Zhu, W; Dai, RC; Wu, XP; Liao, EY; Luo, XH
  • Expression profiling of microRNAs in raw264.7 cells treated with a combination of tumor necrosis factor alpha and rankl during osteoclast differentiation
    Kagiya, T; Nakamura, S
  • MicroRNAs as regulators of bone homeostasis and bone metastasis
    Ell, B; Kang, Y
  • Impaired micro-RNA pathways diminish osteoclast differentiation and function
    Sugatani, T; Hruska, KA
  • MicroRNA-223 is a key factor in osteoclast differentiation
    Sugatani, T; Hruska, KA
  • miR-7b directly targets dc-stamp causing suppression of nfatc1 and c-fos signaling during osteoclast fusion and differentiation
    Dou, C; Zhang, C; Kang, F; Yang, X; Jiang, H; Bai, Y; Xiang, J; Xu, J; Dong, S
  • miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and tgif2
    Krzeszinski, JY; Wei, W; Huynh, H; Jin, Z; Wang, X; Chang, TC; Xie, XJ; He, L; Mangala, LS; Lopez-Berestein, G; Sood, AK; Mendell, JT; Wan, Y
  • MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma
    Campo, S; Allegra, A; D’Ascola, A; Alonci, A; Scuruchi, M; Russo, S; Avenoso, A; Gerace, D; Campo, GM; Musolino, C
  • Bioinformatics analyses of differentially expressed genes associated with bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma
    Sun, J; Wen, X; Jin, F; Li, Y; Hu, J; Sun, Y
  • Genetic inhibition of PPARγ S112 phosphorylation reduces bone formation and stimulates marrow adipogenesis
    Ge, C; Zhao, G; Li, B; Li, Y; Cawthorn, WP; MacDougald, OA; Franceschi, RT
  • Comprehensive genome-wide transcriptomic analysis of immature articular cartilage following ischemic osteonecrosis of the femoral head in piglets
    Adapala, NS; Kim, HK
  • Osteomodulin regulates diameter and alters shape of collagen fibrils
    Tashima, T; Nagatoishi, S; Sagara, H; Ohnuma, S; Tsumoto, K
  • SPARC and the N-propeptide of collagen I influence fibroblast proliferation and collagen assembly in the periodontal ligament
    Rosset, EM; Trombetta-eSilva, J; Hepfer, G; Yao, H; Bradshaw, AD
  • Gene expression profiles induced by growth factors in in vitro cultured osteoblasts
    Robubi, A; Berger, C; Schmid, M; Huber, KR; Engel, A; Krugluger, W
  • miR-15a and miR-16-1 downregulate CCND1 and induce apoptosis and cell cycle arrest in osteosarcoma
    Cai, CK; Zhao, GY; Tian, LY; Liu, L; Yan, K; Ma, YL; Ji, ZW; Li, XX; Han, K; Gao, J; Qiu, XC; Fan, QY; Yang, TT; Ma, BA
  • Sumoylation of p68 and p72 RNA helicases affects protein stability and transactivation potential
    Mooney, SM; Grande, JP; Salisbury, JL; Janknecht, R
  • DEAD-box RNA helicase p68 is not required for nuclear translocation of beta-catenin in colon cancer cells
    Stucke, VM; Gorses, D; Hofmann, F
  • Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells
    Zhan, F; Hardin, J; Kordmeiser, B; Bumm, K; Zheng, M; Tian, E; Sanderson, R; Yang, Y; Wilson, C; Zangari, M; Anaissie, E; Morris, C; Muwalla, F; Rhee, F; Fassas, A; Crowley, J; Tricot, G; Barlogie, B; Shaughnessy, J
  • MicroRNA variants as genetic determinants of bone mass
    Dole, NS; Delany, AM
  • Signalling in osteoclasts and the role of Fos/AP1 proteins
    Wagner, EF; Matsuo, K
  • Fosl1 is a transcriptional target of c-Fos during osteoclast differentiation
    Matsuo, K; Owens, JM; Tonko, M; Elliott, C; Chambers, TJ; Wagner, EF
  • Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems
    Takayanagi, H
  • Isolation and characterization of a cDNA clone encoding a novel peptide (OSF) that enhances osteoclast formation and bone resorption
    Reddy, S; Devlin, R; Menaa, C; Nishimura, R; Choi, SJ; Dallas, M; Yoneda, T; Roodman, GD
  • The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma
    Deng, Z; Niu, G; Cai, L; Wei, R; Zhao, X
  • MiR-17-5p modulates osteoblastic differentiation and cell proliferation by targeting SMAD7 in non-traumatic osteonecrosis
    Jia, J; Feng, X; Xu, W; Yang, S; Zhang, Q; Liu, X; Feng, Y; Dai, Z
  • Increased microRNA-93-5p inhibits osteogenic differentiation by targeting bone morphogenetic protein-2
    Zhang, Y; Wei, QS; Ding, WB; Zhang, LL; Wang, HC; Zhu, YJ; He, W; Chai, YN; Liu, YW
  • Involvement of MicroRNA-210 demethylation in steroid-associated osteonecrosis of the femoral head
    Yuan, HF; Christina, VR; Guo, CA; Chu, YW; Liu, RH; Yan, ZG
  • MiR-708 promotes steroid-induced osteonecrosis of femoral head, suppresses osteogenic differentiation by targeting SMAD3
    Hao, C; Yang, S; Xu, W; Shen, JK; Ye, S; Xianzhe Liu, X; Dong, Z; Xiao, B; Feng, Y
  • Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
    Fanale, D; Amodeo, V; Bazan, V; Insalaco, L; Incorvaia, L; Barraco, N; Castiglia, M; Rizzo, S; Santini, D; Giordano, A; Castorina, S; Russo, A
  • Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets
    Lewis, BP; Burge, CB; Bartel, DP
  • Altered microRNA expression profile in exosomes during osteogenic differentiation of human bone marrow-derived mesenchymal stem cells
    Xu, JF; Yang, GH; Pan, XH; Zhang, SJ; Zhao, C; Qiu, BS; Gu, HF; Hong, JF; Cao, L; Chen, Y; Xia, B; Bi, Q; Wang, YP
  • miR-140-5p suppresses BMP2-mediated osteogenesis in undifferentiated human mesenchymal stem cells
    Hwang, S; Park, SK; Lee, HY; Kim, SW; Lee, JS; Choi, EK; You, D; Kim, CS; Suh, N
  • Murine microRNAs implicated in liver functions and aging process
    Maes, OC; An, J; Sarojini, H; Wang, E
  • MicroRNAs: target recognition and regulatory functions
    Bartel, DP
  • Cooperative and individualistic functions of the microRNAs in the miR-23a~27a~24-2 cluster and its implication in human diseases
    Chhabra, R; Dubey, R; Saini, N
  • Discovery of microvascular miRNAs using public gene expression data: miR-145 is expressed in pericytes and is a regulator of Fli1
    Larsson, E; Fredlund Fuchs, P; Heldin, J; Barkefors, I; Bondjers, C; Genove, G; Arrondel, C; Gerwins, P; Kurschat, C; Schermer, B; Benzing, T; Harvey, SJ; Kreuger, J; Lindahl, P
  • MicroRNAs modulate the angiogenic properties of HUVECs
    Poliseno, L; Tuccoli, A; Mariani, L; Evangelista, M; Citti, L; Woods, K; Mercatanti, A; Hammond, S; Rainaldi, G
  • A novel tumor suppressor miRNA miR-520e contributes to suppression of hepatoma
    Li, BA
  • Osteonecrosis of the jaw and the role of macrophages
    Pazianas, M
  • Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP
    Roelofs, AJ; Jauhiainen, M; Monkkonen, H; Rogers, MJ; Monkkonen, J; Thompson, K
  • Increased CD14+ and decreased CD14- populations of monocytes 48 h after zolendronic acid infusion in breast cancer patients
    Kyrgidis, A; Yavropoulou, MP; Lagoudaki, R; Andreadis, C; Antoniades, K; Kouvelas, D